In May 2022, the group had indicated, as part of an initiative announced at the Davos Economic Forum, that it would supply 23 of its vaccines and patented medicines available in the United States and the European Union to 45 poor countries. - the equivalent of 1.2 billion people.
"Pfizer will now expand its offering under the agreement to include off-patent products, bringing the total of products offered from 23 to approximately 500," the company said in a statement.
These are all products for which Pfizer has worldwide rights, she said.
Selling at cost means that only manufacturing costs and transport expenses will be charged in the countries concerned.
Among the drugs and vaccines concerned are products "that treat or prevent many of the greatest threats of infectious and non-communicable diseases facing low-income countries today", such as antibiotics or chemotherapy, added the business.
"We believe that this expansion of our product offering, combined with continued efforts to help address the barriers that limit or prevent access, will help us realize and even accelerate our vision of a world in which the world has access to the medicines and vaccines needed for a longer and healthier life," Pfizer CEO Albert Bourla said in the statement.
As Pfizer launches other drugs and vaccines, they will also be included in the agreement.
© 2023 AFP